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Clinical background
Kaposi sarcoma-associated herpesvirus (KSHV), also
called human herpesvirus-8 (HHV-8), is the causative
agent of all forms of Kaposi sarcoma (KS), as well as
two rare B-cell HIV lymphoproliferative disorders, pri-
mary effusion lymphoma (PEL) and multicentric Castle-
man’s disease (MCD). Like other herpesviruses, KSHV
has two phases of gene expression, latent and lytic. In
KS, many of the KSHV-infected spindle cells express
only latent genes, while a small percentage express lytic
genes. By contrast, a substantial percentage of MCD
cells express lytic KSHV genes. The majority of PEL
cells express KSHV latent genes, but in addition can
show limited expression of certain lytic genes. Given the
differential expression of KSHV lytic and latent proteins
in KS, PEL, and MCD, we hypothesized that different
antibody profiles to KSHV antigens might distinguish
these diseases.
Materials and methods
Antibodies were evaluated in sera from patients or
volunteers under IRB-approved protocols at the NIH
Clinical Center, NIAID, and the NCI including from
35 patients with KS, 14 with both MCD and KS (MCD
+/KS+), 6 with MCD but no KS (MCD+/KS), 5 with
PEL, and 34 KSHV-uninfected controls. Luciferase
Immunoprecipitation Systems (LIPS) was used for
profiling antibodies to latent and lytic KSHV antigens.
Results
Using LIPS, antibodies against the lytic antigen K8.1
were 5-fold higher in MCD than in KS patients. In con-
trast, markedly higher antibodies to v-cyclin, a latent
K S H Vg e n e ,w e r ef o u n di nt h eK Sa n dP E Lp a t i e n t s
compared to the MCD. Antibodies to another latent
antigen, LANA, were also markedly higher in the KS
compared to the MCD patients. Antibodies to the sum
of latent antigens v-cyclin and LANA were 27-fold
higher in KS compared to MCD patients (p<0.0001).
The sum of anti-v-cyclin and anti-LANA antibody titers
discriminated patients with KS without MCD from
those with MCD and KS with 93% sensitivity and 83%
specificity.
Conclusion
These results suggest that antibody responses to lytic
and latent KSHV antigens differ between KS, MCD, and
PEL.
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